Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

AKT/RSK/S6K inhibitor TAS0612

An orally bioavailable inhibitor of the serine/threonine kinases AKT (protein kinase B), 90S ribosome S6 kinase (p90RSK; RSK) and 70S ribosome S6 kinase (p70S6K; S6K), with potential antineoplastic activity. Upon oral administration, AKT/RSK/S6K inhibitor TAS0612 targets, binds to, and inhibits the activity of AKT, p90RSK and p70S6K. This inhibits both the AKT/mTOR/p70S6K and RAS/RAF/MEK/p90RSK signaling pathways and prevents the phosphorylation, nuclear translocation, and activation of the transcription factor Y-box-binding protein 1 (YBX1; YB-1). This may lead to cell cycle arrest, an induction of apoptosis, and an inhibition of tumor cell proliferation in tumor cells that have overactivated AKT/mTOR/p70S6K and RAS/RAF/MEK/p90RSK signaling pathways. Nuclear expression of YBX1 is associated with drug resistance such as antiestrogen resistance. AKT, RSK and S6K play key roles in tumor cell proliferation, differentiation, survival, and metastasis.
Synonym:AKT/p90RSK/p70S6K inhibitor TAS0612
Code name:TAS 0612
TAS-0612
TAS0612
Search NCI's Drug Dictionary